EZETIMIBE OR STATIN MONOTHERAPY VS CO-ADMINISTRATION IN ETHNIC GROUPS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是比较依替米贝或辛伐他汀单独治疗以及两种药物联合应用在同等数量的非西班牙裔黑人和白人男性中诱导的低密度脂蛋白胆固醇的百分比变化。依折麦布是一种阻止类固醇吸收和辛伐他汀阻止肝脏胆固醇生物合成的药物。需要检验的假设是，黑人对依替米布降低低密度脂蛋白的反应可能比他汀类药物更敏感，因为黑人的胆固醇产量较低。 这将是一项随机、双盲、安慰剂对照、4个周期的交叉研究，共26周，包括3天的筛查期、2周的单盲安慰剂磨合期和4个6周的双盲治疗期。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare the percent change in LDL cholesterol induced by ezitimibe or simvastatin monotherapy and by co-administration of both agents in anequal number of black and White non-Hispanic men. Ezetimibe is a drug that blocks sterol absorption and simvastatin block hepatic cholesterol biosynthesis. The hypothesis to be tested is that Blacks are likely to be more responsive to LDL lowering by ezitimibe than statins because Blacks have a low production of cholesterol. This will be a randomized, double-blind, placebo-controlled, 4-period, crossover study of 26 wekks duration comprising a 3-day screening period; a 2-week, single-blind placebo run-in period; and four 6-week, double-blind treatment periods.